Bastiaan Sallevelt

103 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.5 Continued. START Action Clarity rating Condition Clarity rating Explanation Clarity rating B B1 Regular inhaled B2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) 58% for mild to moderate asthma or COPD. 50% N/A B2 Regular inhaled corticosteroid 58% for moderate-severe asthma or COPD, where FEV1 <50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids. 50% N/A B3 Home continuous oxygen 83% with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%) 92% N/A C C1 L-DOPA or a dopamine agonist 67% in idiopathic Parkinson’s disease with functional impairment and resultant disability. 50% N/A C2 Non-TCA antidepressant drug 25% in the presence of persistent major depressive symptoms. 33% N/A C3 Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) 50% for mild-moderate Alzheimer’s dementia or Lewy Body dementia (rivastigmine). 42% N/A C4 Topical prostaglandin, prostamide or betablocker 67% for primary open-angle glaucoma. 100% N/A C5 Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) 67% for persistent severe anxiety that interferes with independent functioning. 50% N/A C6 Dopamine agonist (ropinirole or pramipexole or rotigotine) 83% for Restless Legs Syndrome, once iron deficiency and severe renal failure have been excluded. 33% N/A 2